PD1-Vaxx is now progressing in colorectal cancers (CRC) in a Phase2 study in earlier lines of disease (pre-surgery). The pivot away from NSCLC to CRC has been made to maximise the potential of PD1-Vaxx for earlier data read outs and for registrational pathways for our product.
Sirwes, thank you for sharing Imugene's future direction for HER-vaxx.
IMO, Imugene's shared study costs V future rewards for the CRC PD1-Vaxx Phase 2 study is exceptional, well done Leslie Chong.(The Australian study costs will qualify for a Government rebate).
Regards.
PD1-Vaxx is now progressing in colorectal cancers (CRC) in a...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.5¢ |
Change
-0.002(4.26%) |
Mkt cap ! $334.7M | |||
| Open | High | Low | Value | Volume |
| 4.7¢ | 4.8¢ | 4.4¢ | $890.8K | 19.42M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 176601 | 4.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.6¢ | 877572 | 7 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |